Open access
2026
Targeted NLRP3 Silencing with Lipopolymer Nanocarriers for Precision Therapy in IL-1β-Mediated Autoinflammatory Diseases
Objectives. Inflammatory diseases could arise from dysregulated innate immunity, often driven by pathogenic activation of the NLRP3 inflammasome, which promotes caspase-1-mediated maturation and secretion of interleukin-1β (IL-1β). While IL-1-blocking biologics...
Mohammad Nasrullah, A. Rajendran, K. C. Bahadur Remant et al.
· RSC Pharmaceutics · 0 citations